<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2026-4569</article-id><article-id custom-type="edn" pub-id-type="custom">ORTXIC</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-4569</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CORONARY HEART DISEASE</subject></subj-group></article-categories><title-group><article-title>Ассоциация синдрома старческой астении с уровнем адипокинов у пациентов со стабильной формой ишемической болезни сердца</article-title><trans-title-group xml:lang="en"><trans-title>Association of frailty with adipokine levels in patients with stable coronary artery disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2384-5682</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кривошапова</surname><given-names>К. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Krivoshapova</surname><given-names>K. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кристина Евгеньевна Кривошапова — д.м.н., с.н.с. лаборатории коморбидности при сердечно-сосудистых заболеваниях </p><p>бульвар имени академика Л. С. Барбараша, д. 6, Кемерово, 650002</p></bio><bio xml:lang="en"><p>Academician Barbarash Boulevard, 6, Kemerovo, 650002</p></bio><email xlink:type="simple">ya.kristi89@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6808-9959</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Неешпапа</surname><given-names>А. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Neeshpapa</surname><given-names>A. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Анастасия Геннадьевна Неешпапа — к.м.н., н.с. лаборатории патологии кровообращения </p><p>бульвар имени академика Л. С. Барбараша, д. 6, Кемерово, 650002</p></bio><bio xml:lang="en"><p>Academician Barbarash Boulevard, 6, Kemerovo, 650002</p></bio><email xlink:type="simple">anastasiyaneeshpapa@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6136-0518</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цыганкова</surname><given-names>Д. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsygankova</surname><given-names>D. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дарья Павловна Цыганкова — д.м.н., в.н.с. лаборатории эпидемиологии сердечно-сосудистых заболеваний </p><p>бульвар имени академика Л. С. Барбараша, д. 6, Кемерово, 650002</p></bio><bio xml:lang="en"><p>Academician Barbarash Boulevard, 6, Kemerovo, 650002</p></bio><email xlink:type="simple">darjapavlovna2014@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3023-6239</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баздырев</surname><given-names>Е. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Bazdyrev</surname><given-names>E. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Евгений Дмитриевич Баздырев — д.м.н., зав. лабораторией эпидемиологии сердечно-сосудистых заболеваний </p><p>бульвар имени академика Л. С. Барбараша, д. 6, Кемерово, 650002</p></bio><bio xml:lang="en"><p>Academician Barbarash Boulevard, 6, Kemerovo, 650002</p></bio><email xlink:type="simple">edb624@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9801-9839</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каретникова</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Karetnikova</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Виктория Николаевна Каретникова — д.м.н., профессор, зав. лабораторией патологии кровообращения </p><p>бульвар имени академика Л. С. Барбараша, д. 6, Кемерово, 650002</p></bio><bio xml:lang="en"><p>Academician Barbarash Boulevard, 6, Kemerovo, 650002</p></bio><email xlink:type="simple">tori1071@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4642-3610</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Барбараш</surname><given-names>О. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Barbarash</surname><given-names>O. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ольга Леонидовна Барбараш — д.м.н., проф., академик РАН, директор </p><p>бульвар имени академика Л. С. Барбараша, д. 6, Кемерово, 650002</p></bio><bio xml:lang="en"><p>Academician Barbarash Boulevard, 6, Kemerovo, 650002</p></bio><email xlink:type="simple">olb61@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ "Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний" Министерства науки и высшего образования Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute for Complex Issues of Cardiovascular Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute for Complex Issues of Cardiovascular Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>29</day><month>04</month><year>2026</year></pub-date><volume>25</volume><issue>3</issue><fpage>4569</fpage><lpage>4569</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кривошапова К.Е., Неешпапа А.Г., Цыганкова Д.П., Баздырев Е.Д., Каретникова В.Н., Барбараш О.Л., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Кривошапова К.Е., Неешпапа А.Г., Цыганкова Д.П., Баздырев Е.Д., Каретникова В.Н., Барбараш О.Л.</copyright-holder><copyright-holder xml:lang="en">Krivoshapova K.E., Neeshpapa A.G., Tsygankova D.P., Bazdyrev E.D., Karetnikova V.N., Barbarash O.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/4569">https://cardiovascular.elpub.ru/jour/article/view/4569</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучить ассоциации между степенью выраженности проявлений синдрома старческой астении (ССА) и концентрацией адипокинов в сыворотке крови пациентов с ишемической болезнью сердца (ИБС) перед чрескожным коронарным вмешательством (ЧКВ).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В одноцентровое когортное исследование было включено 174 пациента с ИБС, поступивших в клинику с целью проведения планового ЧКВ. Средний возраст пациентов изучаемой выборки составил 67,38±8,31 лет, лица мужского пола встречались в 61,5% случаев. Для скрининга преастении и ССА был использован опросник "Возраст не помеха" (1-2 балла — старческая астения отсутствует, 3-4 балла — преастения, ≥5 баллов — старческая астения). Для определения концентрации биологических маркеров ремоделирования жировой ткани в сыворотке крови пациентов применялся высокочувствительный и высокоспецифичный метод иммуноферментного анализа с использованием наборов — AssayMax Human Adiponectin (ACRP30) ELISA Kit (USA), Diagnostics Biochem Canada Inc. Leptin ELISA Kit (London, Ontario, Canada), BioVendor R&amp;D Human Resistin ELISA Kit (Czech Republic), BioVendor R&amp;D Human Chemerin ELISA Kit (Czech Republic).</p></sec><sec><title>Результаты</title><p>Результаты. Частота выявления преастении среди пациентов с ИБС на основании баллов по опроснику "Возраст не помеха" составила 38,0%, ССА — 8,6%, при этом значимо чаще "хрупкими" пациентами перед плановым ЧКВ были женщины более пожилого возраста. Корреляционный анализ показал наличие значимых ассоциаций между баллами по опроснику "Возраст не помеха" и концентрацией в сыворотке крови пациентов изучаемой выборки хемерина (ρ=0,283, р=0,030), лептина (ρ=0,289, р=0,017), резистина (ρ=0,235, р=0,043) и адипонектина (ρ=-0,338, р=0,039), а также возрастом (ρ=0,200, р=0,008). В результате бинарной логистической регрессии, из всех изучаемых в исследовании предикторов, была подтверждена статистически значимая связь только между наличием ССА по данным опросника "Возраст не помеха" и более низким уровнем адипонектина в сыворотке крови пациентов со стабильной формой ИБС (площадь под кривой (AUC)=0,766; 95% доверительный интервал: 0,643-0,889, p=0,013).</p></sec><sec><title>Заключение</title><p>Заключение. Выявлены статистически значимые ассоциации между степенью выраженности проявлений ССА и концентрацией адипокинов в сыворотке крови пациентов с ИБС перед плановым ЧКВ.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To study the associations between the severity of frailty manifestations and serum adipokine levels in patients with coronary artery disease (CAD) before percutaneous coronary intervention (PCI).</p></sec><sec><title>Material and methods</title><p>Material and methods. This single-center cohort study included 174 patients with CAD admitted to hospital for elective PCI. The mean age of patients in the study sample was 67,38±8,31 years (men, 61,5%). The "Age Is Not a Barrier" questionnaire was used to screen for pre-frailty and frailty (1-2 — no frailty, 3-4 — pre-frailty, ≥5 — frailty). A highly sensitive and highly specific enzyme-linked immunosorbent assay (ELISA) was used to determine the concentration of serum biological markers of adipose tissue remodeling. The following kits were used: AssayMax Human Adiponectin (ACRP30) ELISA Kit (USA), Diagnostics Biochem Canada Inc. Leptin ELISA Kit (London, Ontario, Canada), BioVendor R&amp;D Human Resistin ELISA Kit (Czech Republic), and BioVendor R&amp;D Human Chemerin ELISA Kit (Czech Republic).</p></sec><sec><title>Results</title><p>Results. The incidence of pre-frailty among patients with CAD based on the "Age Is Not a Barrier" scores was 38,0%, and that of frailty was 8,6%. Moreover, "frail" patients before elective PCI were significantly more often older women. Correlation analysis revealed significant associations between the "Age Is Not a Barrier" scores and the serum concentrations of chemerin (ρ=0,283, p=0,030), leptin (ρ=0,289, p=0,017), resistin (ρ=0,235, p=0,043), and adiponectin (ρ=-0,338, p=0,039), as well as age (ρ=0,200, p=0,008). Binary logistic regression confirmed a significant association between the frailty according to the "Age is not a barrier" questionnaire and lower serum adiponectin levels in patients with stable CAD (AUC=0,766; 95% confidence interval: 0,643-0,889, p=0,013) among all the predictors examined in the study.</p></sec><sec><title>Conclusion</title><p>Conclusion. Significant associations were found between the severity of frailty manifestations and serum adipokine concentrations in patients with CAD before elective PCI.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>преастения</kwd><kwd>синдром старческой астении</kwd><kwd>ишемическая болезнь сердца</kwd><kwd>адипокины</kwd><kwd>лептин</kwd><kwd>адипонектин</kwd><kwd>резистин</kwd><kwd>хемерин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>pre-frailty</kwd><kwd>frailty</kwd><kwd>coronary artery disease</kwd><kwd>adipokines</kwd><kwd>leptin</kwd><kwd>adiponectin</kwd><kwd>resistin</kwd><kwd>chemerin</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Вавилова Т. П., Плетень А. П., Михеев Р. К. Биологическая роль адипокинов как маркеров патологических состояний. Вопросы питания. 2017;86(2):5-13. doi:10.24411/0042-8833-2017-00028.</mixed-citation><mixed-citation xml:lang="en">Vavilova TP, Pleten’ AP, Mikheev RK. Biological role of adipokines and their association with morbid conditions. Voprosy pitaniia. 2017;86(2):5-13. (In Russ.) doi:10.24411/0042-8833-2017-00028.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Дзугкоев С. Г., Дзугкоева Ф. С., Можаева И. В. и др. Адипокины, ожирение и метаболические нарушения. Современные проблемы науки и образования. 2020;(6):201. doi:10.17513/spno.30321.</mixed-citation><mixed-citation xml:lang="en">Dzugkoev SG, Dzugkoeva FS, Mozhaeva IV, et al. Adipokines, obesity and metabolic disorders. Modern problems of science and education. 2020;(6):201. (In Russ.) doi:10.17513/spno.30321.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Мартюшев-Поклад А. В., Янкевич Д. С., Петрова М. В. и др. Две модели развития инсулинорезистентности и стратегия борьбы с возрастзависимыми заболеваниями: обзор литературы. Проблемы эндокринологии. 2022;68(4):59-68. doi:10.14341/probl13090.</mixed-citation><mixed-citation xml:lang="en">Martyushev-Poklad AV, Yankevich DS, Petrova MV, et al. Two models of insulin resistance development and the strategy to combat age-related diseases: literature review. Problems of endocrinology. 2022;68(4):59-68. (In Russ.) doi:10.14341/probl13090.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Unger RH. Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine. Biochimie. 2005;87(1):57-64. doi:10.1016/j.biochi.2004.11.014.</mixed-citation><mixed-citation xml:lang="en">Unger RH. Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine. Biochimie. 2005;87(1):57-64. doi:10.1016/j.biochi.2004.11.014.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Котовская Ю. В., Ткачева О. Н., Рунихина Н. К. и др. Изучение долгожительства: современный статус проблемы и перспективы. Часть 2. Кардиоваскулярная терапия и профилактика. 2017;16(6):133-8. doi:10.15829/1728-8800-2017-6-133-138.</mixed-citation><mixed-citation xml:lang="en">Kotovskaya YuV, Tkacheva ON, Runikhina NK, et al. The study of longevity: recent updates and further direction. Part 2. Cardiovascular Therapy and Prevention. 2017;16(6):133-8. (In Russ.) doi:10.15829/1728-8800-2017-6-133-138.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Бояринова М. А., Ротарь О. П., Кондради А. О. Адипокины и кардиометаболический синдром. Артериальная гипертензия. 2014;20(5):422-32. EDN: TAIGXD.</mixed-citation><mixed-citation xml:lang="en">Boyarinova MA, Rotar OP, Konradi AO. Adipokines and cardiometabolic syndrome. Arterial Hypertension. 2014;20(5):422-32. (In Russ.) EDN: TAIGXD.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Rondinone CM. Adipocyte-derived hormones, cytokines, and mediators. Endocrine. 2006;29(1):81-90. doi:10.1385/endo:29:1:81.</mixed-citation><mixed-citation xml:lang="en">Rondinone CM. Adipocyte-derived hormones, cytokines, and mediators. Endocrine. 2006;29(1):81-90. doi:10.1385/endo:29:1:81.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Taouis M, Benomar YIs resistin the master link between inflammation and inflammation-related chronic diseases? Mol Cell Endocrinol. 2021;533:111341. doi:10.1016/j.mce.2021.111341.</mixed-citation><mixed-citation xml:lang="en">Taouis M, Benomar YIs resistin the master link between inflammation and inflammation-related chronic diseases? Mol Cell Endocrinol. 2021;533:111341. doi:10.1016/j.mce.2021.111341.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Lehrke M, Becker A, Greif M, et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol. 2009;161(2):339-44. doi:10.1530/EJE-09-0380.</mixed-citation><mixed-citation xml:lang="en">Lehrke M, Becker A, Greif M, et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol. 2009;161(2):339-44. doi:10.1530/EJE-09-0380.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Shibasaki K, Yamada S, Akishita M, et al. Plasma Leptin Concentration and Sympathetic Nervous Activity in Older Adults With Physical Dysfunction. J Endocr Soc. 2018;2(9):1040-9. doi:10.1210/js.2018-00104.</mixed-citation><mixed-citation xml:lang="en">Shibasaki K, Yamada S, Akishita M, et al. Plasma Leptin Concentration and Sympathetic Nervous Activity in Older Adults With Physical Dysfunction. J Endocr Soc. 2018;2(9):1040-9. doi:10.1210/js.2018-00104.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ma L, Sha G, Zhang Y, et al. Elevated serum IL-6 and adiponectin levels are associated with frailty and physical function in Chinese older adults. Clin Interv Aging. 2018;13:2013-20. doi:10.2147/CIA.S180934.</mixed-citation><mixed-citation xml:lang="en">Ma L, Sha G, Zhang Y, et al. Elevated serum IL-6 and adiponectin levels are associated with frailty and physical function in Chinese older adults. Clin Interv Aging. 2018;13:2013-20. doi:10.2147/CIA.S180934.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019;41(3):407-77. doi:10.1093/eurheartj/ehz425.</mixed-citation><mixed-citation xml:lang="en">Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019;41(3):407-77. doi:10.1093/eurheartj/ehz425.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ткачева О. Н., Котовская Ю. В., Рунихина Н. К. и др. Клинические рекомендации "Старческая астения". Российский журнал гериатрической медицины. 2025; (1):6-48. doi:10.37586/2686-8636-1-2025-6-48.</mixed-citation><mixed-citation xml:lang="en">Tkacheva ON, Kotovskaya YuV, Runikhina NK, et al. Clinical Guidelines on Frailty. Russian Journal of Geriatric Medicine. 2025;(1):6-48. (In Russ.) doi:10.37586/2686-8636-1-2025-6-48.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Vermeiren S, Vella-Azzopardi R, Beckwée D, et al. Frailty and the Prediction of Negative Health Outcomes: A Meta-Analysis. J Am Med Dir Assoc. 2016;17(12):1163.e1-1163.e17. doi:10.1016/j.jamda.2016.09.010.</mixed-citation><mixed-citation xml:lang="en">Vermeiren S, Vella-Azzopardi R, Beckwée D, et al. Frailty and the Prediction of Negative Health Outcomes: A Meta-Analysis. J Am Med Dir Assoc. 2016;17(12):1163.e1-1163.e17. doi:10.1016/j.jamda.2016.09.010.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Nagasawa M, Takami Y, Akasaka H, et al. High plasma adiponectin levels are associated with frailty in a general old-old population: The Septuagenarians, Octogenarians, Nonagenarians Investigation with Centenarians study. Geriatr Gerontol Int. 2018;18(6): 839-46. doi:10.1111/ggi.13258.</mixed-citation><mixed-citation xml:lang="en">Nagasawa M, Takami Y, Akasaka H, et al. High plasma adiponectin levels are associated with frailty in a general old-old population: The Septuagenarians, Octogenarians, Nonagenarians Investigation with Centenarians study. Geriatr Gerontol Int. 2018;18(6): 839-46. doi:10.1111/ggi.13258.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Arai Y, Nakazawa S, Kojima T, et al. High adiponectin concentration and its role for longevity in female centenarians. Geriatrics&amp;Gerontology International. 2006;6:32-9. doi:10.1111/j.1447-0594.2006.00304.x.</mixed-citation><mixed-citation xml:lang="en">Arai Y, Nakazawa S, Kojima T, et al. High adiponectin concentration and its role for longevity in female centenarians. Geriatrics&amp;Gerontology International. 2006;6:32-9. doi:10.1111/j.1447-0594.2006.00304.x.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Paolisso G, Ammendola S, Del Buono A, et al. Serum levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in healthy centenarians: relationship with plasma leptin and lipid concentrations, insulin action, and cognitive function. J Clin Endocrinol Metab. 1997;82(7):2204-9. doi:10.1210/jcem.82.7.4087.</mixed-citation><mixed-citation xml:lang="en">Paolisso G, Ammendola S, Del Buono A, et al. Serum levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in healthy centenarians: relationship with plasma leptin and lipid concentrations, insulin action, and cognitive function. J Clin Endocrinol Metab. 1997;82(7):2204-9. doi:10.1210/jcem.82.7.4087.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Baranowska B, Bik W, Baranowska-Bik A, et al. Neuroendocrine control of metabolic homeostasis in polish centenarians. J Physiol Pharmacol. 2006;57(6):55-61.</mixed-citation><mixed-citation xml:lang="en">Baranowska B, Bik W, Baranowska-Bik A, et al. Neuroendocrine control of metabolic homeostasis in polish centenarians. J Physiol Pharmacol. 2006;57(6):55-61.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Lana A, Valdés-Bécares A, Buño A, et al. Serum leptin concentration is associated with incident frailty in older adults. Aging Dis. 2017;8(2):240-9. doi:10.14336/AD.2016.0819.</mixed-citation><mixed-citation xml:lang="en">Lana A, Valdés-Bécares A, Buño A, et al. Serum leptin concentration is associated with incident frailty in older adults. Aging Dis. 2017;8(2):240-9. doi:10.14336/AD.2016.0819.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Westbrook RM, Yang HL, Langdon JM, et al. Aged interleukin-10tm1Cgn chronically inflamed mice have substantially reduced fat mass, metabolic rate, and adipokines. PLoS One. 2017;12(12):e0186811. doi:10.1371/journal.pone.0186811.</mixed-citation><mixed-citation xml:lang="en">Westbrook RM, Yang HL, Langdon JM, et al. Aged interleukin-10tm1Cgn chronically inflamed mice have substantially reduced fat mass, metabolic rate, and adipokines. PLoS One. 2017;12(12):e0186811. doi:10.1371/journal.pone.0186811.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kim BJ, Jo Y, Baek JY, et al. Higher serum resistin levels and increased frailty risk in older adults: Implications beyond metabolic function. J Nutr Health Aging. 2025;29(5):100521. doi:10.1016/j.jnha.2025.100521.</mixed-citation><mixed-citation xml:lang="en">Kim BJ, Jo Y, Baek JY, et al. Higher serum resistin levels and increased frailty risk in older adults: Implications beyond metabolic function. J Nutr Health Aging. 2025;29(5):100521. doi:10.1016/j.jnha.2025.100521.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Fülöp P, Seres I, Lőrincz H, et al. Association of chemerin with oxidative stress, inflammation and classical adipokines in non-diabetic obese patients. J Cell Mol Med. 2014;18(7):1313-20. doi:10.1111/jcmm.12282.</mixed-citation><mixed-citation xml:lang="en">Fülöp P, Seres I, Lőrincz H, et al. Association of chemerin with oxidative stress, inflammation and classical adipokines in non-diabetic obese patients. J Cell Mol Med. 2014;18(7):1313-20. doi:10.1111/jcmm.12282.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Arai Y, Takayama M, Abe Y, et al. Adipokines and aging. J Atheroscler Thromb. 2011;18(7):545-50. doi:10.5551/jat.7039.</mixed-citation><mixed-citation xml:lang="en">Arai Y, Takayama M, Abe Y, et al. Adipokines and aging. J Atheroscler Thromb. 2011;18(7):545-50. doi:10.5551/jat.7039.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
